Company: BGLC
Filing Date: 2025-11-14
Form Type: PRE 14A
Source: 0001477932-25-008317
Chunk: 11

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: PRE 14A
Chunk 11
---
 reason to believe that any nominee will be unavailable to serve.

Nominees

The following table sets forth the name, age and positions of each of our director nominees as of the date of this Proxy Statement. Each of the nominees listed below is currently a director of the Company and has been elected to serve until our next annual meeting of stockholders or until their respective successors are duly elected and qualified.

| Name                           |     | Age |     | Position                                                                                                                                       |
| Su-Leng Tan Lee                |     |  42 |     | Chief Executive Officer, President, and Director                                                                                               |
| Jook Yuen Low                  |     |  48 |     | Director, Member of Audit and Nominating Committees                                                                                            |
| Muhammad Azrul bin Abdul Hamid |     |  50 |     | Director, Member of the Audit Committee, Chairman of the Compensation Committee, Chairman of the Corporate Governance and Nominating Committee |
| Chee Keong Yap                 |     |  70 |     | Director, Chairman of the Audit Committee, Member of the Compensation Committee                                                                |

Business Experience and Directorships

The following describes the background of our directors.

Su-Leng Tan Lee has been a Director of the Company since December 2023, and has over 20 years of extensive experience in a variety of industries, including information systems, hospitality, investment management, construction, property development, travel, government liaison, and life sciences, primarily focused on commercialization, finance, and general management. Since August 2023, Mr. Tan has served as the Company’s Chief Operating Officer. Since May 2022, Mr. Tan worked as the Chief Commercial Officer for Dryox Health Limited, a startup focused on repurposing drugs for unmet needs in the dermatological space, specifically anticholinergic drugs. Since August 2017, Mr. Tan worked as the FLO Life Sciences Group’s owner and Managing Director, focusing on infectious diseases and oncology pre-clinical drug candidates and clinical research. From July 2018 to April 2019, Mr. Tan was the President of Avillion Berhad, a publicly listed travel and hospitality group with hotels, commercial property, and inbound/outbound travel services. The Company believes Mr. Tan is qualified to serve as the Company’s Chief Executive Officer and a member of the Board due to his extensive experience with biotech and pharmaceutical companies.

| 8 |

Jook Yuen Low has been a director of the Company since November, 2024